Juniper invests in mixer tech for UK plant
The UK-based contract manufacturing organization (CMO) – a subsidiary of Nasdaq-listed Juniper Pharmaceuticals – has bought, installed and validated a Becomix homogenizer. The technology will be used to make creams, ointments and semi-solids for clinical trials.
Claire Madden-Smith, SVP at Juniper, said: “This addition to our capabilities enables us to develop topical products on a larger scale and to cater for our clients’ supply needs from first-in-man studies up to and including Phase III, with a commercially replicable process in place.
At the end of last year Juniper bought a Xcelodose powder micro-dosing system for the facility and earlier this month it ordered a PSD-1 GEA Niro spray dryer for the Nottingham. On both occasions it said customer demand had prompted the investment.
The mixer was also bought with clients in mind according to Madden-Smith.
“We are no stranger to aiding clients with challenging formulations and so the installation of Becomix simply bolsters our ability to support drug development companies that are developing creams, ointments, and semi-solid products, both simple and complex.”
